Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance

Cassava Sciences IncTrade
Vanguard Intermediate Term Corporate Bond ETFTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.18. Which is the better fit depends on your goals.

FLNAVCIT
Market Cap
$47.75M
Sector
HealthFixed Income
52-Week High
$4.64$84.82
52-Week Low
$0.87$81.07
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Vanguard Intermediate Term Corporate Bond ETF

VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.42, up 0.17% over 24 hours. The technical outlook is neutral with bearish moving averages, while recent news highlights its low 0.03% expense ratio and competitive yield. Dividend distributions are scheduled through mid-2026, providing steady income.

The ETF offers a balance of yield and moderate risk through investment-grade corporate bonds. Key risks include interest rate sensitivity and economic volatility. Analyst sentiment is mixed, emphasizing cost efficiency but cautioning on duration exposure in a shifting rate environment.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Vanguard Intermediate Term Corporate Bond ETF

VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.

Read more on VCIT